» Articles » PMID: 30678785

Catheter Ablation of Ventricular Tachycardia in Patients With a Ventricular Assist Device: A Systematic Review of Procedural Characteristics And Outcomes

Overview
Date 2019 Jan 26
PMID 30678785
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This is a systematic review summarizing the procedural characteristics and outcomes of ventricular assist device (VAD)-related ventricular tachycardia (VT) ablation.

Background: Drug-refractory VT refractory commonly develops post-VAD implantation. Procedural and outcome data come from small series or case reports.

Methods: An electronic search was performed using major databases. Primary outcomes were VT recurrence, mortality, and cardiac transplantation. Secondary endpoints were acute procedural success and procedural complications.

Results: Eighteen studies were included, with a total of 110 patients (mean age 59.6 ± 11 years, 89% men; VT storm 34%). Scar-related re-entry was the predominant mechanism of VT (90.3%) and cannula-related VT in 19.3% cases. Electroanatomical mapping interference occurred in 1.8% of cases; there were no reports of catheter entrapment. Noninducibility of clinical VT was achieved in 77.9%; procedural complications occurred in 9.4%. At a mean follow-up of 263.5 ± 267.0 days, VT recurred in 43.6%, 23.4% underwent cardiac transplant, and 48.1% died. There were no procedural-related deaths and no death was directly related to ventricular arrhythmia. In follow-up, there was a significant reduction in implantable cardioverter-defibrillator therapies or shocks (57.1% vs. 23.8%). Ablation allowed VT storm termination in 90% of patients.

Conclusions: VAD-related VT is predominantly related to pre-existing intrinsic myocardial scar rather than inflow cannula site insertion. Catheter ablation is a reasonable treatment strategy, albeit with expectedly high rate of recurrence, transplantation, and mortality related to severe underlying disease.

Citing Articles

[Role of ventricular tachycardia ablation in patients with systolic heart failure].

Ebert M, Thomsen Y, Richter S Herzschrittmacherther Elektrophysiol. 2025; 36(1):10-20.

PMID: 39843809 DOI: 10.1007/s00399-024-01064-4.


Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC.

Peichl P, Bayes-Genis A, Deneke T, Chioncel O, deRiva M, Crespo-Leiro M Europace. 2024; 26(11).

PMID: 39478667 PMC: 11580222. DOI: 10.1093/europace/euae272.


Percutaneous mechanical support in catheter ablation of ventricular arrhythmias: hype or hope?.

Kautzner J, Haskova J, Stojadinovic P, Peichl P, Wichterle D Europace. 2024; 26(7).

PMID: 39028767 PMC: 11259133. DOI: 10.1093/europace/euae186.


Simultaneous epicardial ablation based on intraoperative electroanatomic mapping during left ventricular assist device implantation.

Nishino K, Watanabe M, Ooka T, Sato T, Anzai T J Arrhythm. 2024; 40(3):632-635.

PMID: 38939782 PMC: 11199846. DOI: 10.1002/joa3.13029.


The Influence of Arrhythmias and Metabolic Profile on Inpatient Mortality in Patients with Left Ventricular Assist Devices.

Antwi-Amoabeng D, Beutler B, Gbadebo T J Clin Med. 2024; 13(6).

PMID: 38541962 PMC: 10971143. DOI: 10.3390/jcm13061737.